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Human African 
Trypanosomiasis in 
Areas without 
Surveillance
To the Editor: Human African 
trypanosomiasis (HAT), sleeping 
sickness, is a systemic protozoan 
disease transmitted by the bite of a 
tsetse fl y; untreated infection is fatal 
(1). Control of HAT caused by Try-
panosoma brucei gambiense, which 
caused 97% of all cases reported 
from 1997 through 2006 (2), is based 
on active screening of the population 
at risk by mobile teams and treatment 
of all infected persons, with or with-
out vector control.
The epidemiologic curve of re-
ported new cases varies considerably; 
incidence peaks were high in the 1920s 
and 1990s but low in the 1960s and in 
the past decade (2000–2009) (2–4). 
The recent reduction of reported cas-
es (69% decrease from 1997 through 
2006) was made possible by 1) cessa-
tion of large-scale civil wars (e.g., in 
Angola); 2) increased commitment of 
donors, national control programs, the 
World Health Organization (WHO), 
and nongovernment organizations; 
and 3) free production and supply of 
antitrypanosomal drugs. In May 2007, 
after a WHO informal consultation 
on sustainable sleeping sickness con-
trol, representatives from countries 
to which HAT is endemic concluded 
that HAT elimination is possible (5). 
Médecins sans Frontières (MSF), an 
international nongovernment organi-
zation, wishes to challenge this con-
clusion.
Because of insuffi cient coverage 
by surveillance systems, only a frac-
tion of HAT cases are reported. In 
2004, for example, although WHO 
received reports of only 17,500 new 
cases, they estimated that the actual 
incidence was 50,000–70,000 cases 
(6). Recent MSF HAT projects in re-
mote and politically unstable areas of 
the Central African Republic and the 
Democratic Republic of Congo are 
fi nding new information about the 
location and nature of some of these 
blind spots (areas without surveil-
lance) (Table).
In the zones de santé (administra-
tive districts) of Doruma, Ango, and 
Bili, in northeastern Democratic Re-
public of Congo, no HAT control ac-
tivities have taken place over the past 
3 decades, mainly because of extreme 
remoteness of these areas. In July 
2007, MSF launched a HAT control 
program and found high (3.4%) dis-
ease prevalence and a large propor-
tion of patients in the fi rst stage of 
the disease (60%), indicating intense 
transmission. In March 2009, the MSF 
team was attacked by rebels from the 
Lord’s Resistance Army, leading to 
total suspension of the project for an 
indefi nite period. The lack of trained 
staff in existing health structures and 
the complexity of HAT management 
prevented emergency handover of the 
project to local partners.
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Batangafo and Maitikoulou, in 
northwestern Central African Re-
public, are also historical foci of 
HAT that have been neglected over 
the past years, mainly because of 
political insecurity and logistic con-
straints. From January 2007 through 
April 2009, HAT was diagnosed for 
1,074 patients in Batangafo (preva-
lence 3.1%). From January through 
May 2009, MSF screening of 4,633 
persons from 23 villages around Mai-
tikoulou in Central African Republic 
and Chad found high disease preva-
lence and a high proportion of fi rst-
stage illness.
Because the case-fi nding activities 
in the Central African Republic and 
Democratic Republic of Congo were 
restricted for security reasons, the MSF 
programs may only be seeing a small 
part of the problem. The above-listed 
examples illustrate that many HAT pa-
tients are still found in historical foci 
that have been devoid of active surveil-
lance for years or decades because of 
their remoteness, insecurity, neglect, or 
a combination of these factors. Thus, 
many more patients probably continue 
to have no access to care and therefore 
remain invisible.
We emphasize the crucial need 
to continue research and develop-
ment efforts toward simpler diagnos-
tic methods and treatment. The effect 
of inadequate tools is particularly ob-
vious in remote or unstable areas of 
high disease prevalence, where health 
facilities are often poorly functioning 
and severely understaffed. The recent 
completion of a study showing excel-
lent safety and effi cacy of a simpler 
treatment for second-stage patients is 
an encouraging fi rst step (7).
The remoteness of many HAT-en-
demic areas, persistence of forgotten 
confl icts, and insuffi cient resources 
continue to restrict the possibility of 
eliminating HAT, except in countries 
or regions where the disease is already 
well controlled or where control pro-
grams cover all disease-endemic foci. 
As long as most HAT patients contin-
ue to have no access to care and are 
therefore not reported, HAT cannot be 
eliminated. Moreover, countrywide 
statistics should be interpreted with 
caution. The decline of new cases 
observed in the Democratic Republic 
of Congo from 1998 through 2003 is 
largely the result of efforts of 1 non-
government organization in 1 prov-
ince (Equateur-Nord), while the inci-
dence trends remained stable in other 
provinces (8).
Donors must be aware that HAT 
epidemiology is heterogeneous. The 
allocation of funds should not be re-
stricted to maintaining surveillance 
and control efforts in areas of low 
disease prevalence (to prevent future 
fl are-ups). Adequate funding must also 
be provided to allow control programs 
to reach remote disease-endemic foci 
that have been left without active sur-
veillance for years.
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Table. Human African trypanosomiasis control programs run by Médecins sans Frontières in central Africa, January 2007–May 2009*
No. persons screened No. (%) new diagnoses 
Location (program dates) Total Passive Active Total First stage Second stage 
Prevalence,
%†
Zones de santé of Doruma, Ango and 
Bili, DRC (2007 Jul–2009 Mar)
46,601 18,559 28,042 1,570 947 (60) 623 (40) 3.4
Maitikoulou and neighboring villages, 
CAR and Chad (2009 Jan–2009 May) 
4,633 286 4,347 665 450 (68) 215 (32) 14.4
*DRC, Democratic Republic of Congo; CAR, Central African Republic. 
†Total no. patients with parasitologically confirmed human African trypanosomiasis (total no. new diagnoses) divided by total no. persons screened during 
the period of first-round active screening (total no. persons screened).
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Using Museum 
Collections to 
Detect Pathogens
To the Editor: Natural history 
museum collections have evolved in 
recent years to meet the challenges 
of current and future interdisciplinary 
scientifi c studies. Many natural his-
tory museums have built tissue col-
lections and made digital information 
(e.g., photographs, publications, geo-
graphic coordinates) freely available 
on the Internet. These collections pro-
vide endless opportunities to conduct 
studies, including temporal and spatial 
surveys of emerging and reemerging 
pathogens (1). We report an example 
of a museum collection being useful in 
detecting Trypanosoma cruzi, the etio-
logic agent of Chagas disease, in the 
southern plains woodrat (Neotoma mi-
cropus) in southern Texas. This fi nd-
ing is of interest in the epidemiology 
of Chagas disease because the climatic 
characteristics and demographics of 
the region are similar to areas in Latin 
America where Chagas disease is an 
important zoonotic agent that infects 
≈20 million persons (2).
Tissue samples from N. micropus 
woodrats archived in the Natural Sci-
ence Research Laboratory at the Mu-
seum of Texas Tech University were 
evaluated for T. cruzi DNA by PCR 
methods. All samples were originally 
collected during March 2001–June 
2003 from the Chaparral Wildlife 
Management Area in southern Texas 
(28º18′N, 99º24′W), 86 km west of 
the Mexico–US border; some samples 
had been used previously in other re-
search projects (3). Individual rodents 
were captured with live traps (n = 13) 
or by excavating middens in which 
all the nest occupants were collect-
ed by hand (n = 146). Animals were 
later euthanized and tissue samples 
(heart, kidney, liver, lung, muscle, 
spleen) were obtained. Tissues were 
immediately frozen in liquid nitrogen 
and permanently stored in ultralow-
temperature freezers. We extracted 1 
DNA sample from each animal’s liver 
for use in this survey. DNA amplifi ca-
tion was performed by using primers 
specifi c to T. cruzi (TCZ1 and TCZ2) 
(4) under previously standardized 
conditions and positive controls (5). T. 
cruzi DNA was detected in 42 (26.4%) 
of 159 woodrat samples tested. Males 
were infected signifi cantly more of-
ten (31/82) than females (11/73); sex 
was not determined for 4 individuals 
(Score test for a binomial proportion, 
z = –4.0, p<0.01). Adults had a nonsig-
nifi cant higher prevalence (24/92) than 
all other individuals in the remaining 
age categories combined (14/54) (age 
was not determined for 13 individuals) 
(Score test for a binomial proportion, 
z = –0.02, p = 0.98). Middens that 
harbored infected individuals (n = 28, 
mean = 1.8) were not signifi cantly (t = 
0.79, df = 84, p = 0.43) more populated 
than middens that harbored uninfected 
individuals (n = 58, mean = 1.6).
Woodrats had been shown by using 
microscopy to be infected by T. cruzi 
and T. cruzi–like organisms (6); how-
ever, no defi nitive DNA-based confi r-
mation had been performed (6,7). The 
results of this research confi rm the in-
fection of N. micropus woodrats with 
T. cruzi and show a higher prevalence 
than that reported in previous studies 
that used other diagnostic methods. 
These results also point to woodrats 
as a potentially important reservoir 
of T. cruzi in North America. We hy-
pothesize that the high prevalence is 
a consequence of the nest-building 
habits of these rodents. These nests 
are complexes of dry branches, grass-
es, and leaves, with a mean diameter 
of 84 cm, and offer easy access and 
permanent refuge to triatomine bugs. 
Woodrats have been found in associa-
tion with at least 5 triatomine species: 
Triatoma gerstaeckeri, T. lecticularia, 
T. neotomae, T. protracta, and T. san-
guisuga (8). Another factor for consid-
eration is woodrats’ multigenerational 
midden use, which may enable the 
permanent occurrence of triatomine 
colonies and therefore maintain long-
term circulation of T. cruzi. Whereas 
recent characterizations of North 
American strains have included iso-
lates from other mammalian reservoir 
hosts (9), the genotyping of parasites 
from N. micropus woodrats and other 
woodrats is still to be done.
Despite successful results from 
tracking pathogens by using material 
deposited in natural history museum 
collections (10), this practice is not 
common. We suggest that natural his-
tory museum collections be used more 
frequently, especially for surveying 
and genotyping T. cruzi in mammals, 
because of the importance of such in-
formation in clarifying the epidemiol-
ogy and the evolutionary history of 
this pathogen. 
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